BR112014010644A2 - novos derivados de aril-quinolina - Google Patents

novos derivados de aril-quinolina

Info

Publication number
BR112014010644A2
BR112014010644A2 BR112014010644A BR112014010644A BR112014010644A2 BR 112014010644 A2 BR112014010644 A2 BR 112014010644A2 BR 112014010644 A BR112014010644 A BR 112014010644A BR 112014010644 A BR112014010644 A BR 112014010644A BR 112014010644 A2 BR112014010644 A2 BR 112014010644A2
Authority
BR
Brazil
Prior art keywords
quinoline derivatives
new aryl
aryl quinoline
compounds
new
Prior art date
Application number
BR112014010644A
Other languages
English (en)
Inventor
Conte Aurelia
Kuhn Bernd
Kuehne Holger
Rudolph Markus
M Ceccarelli Simona
Obst Sander Ulrike
Neidhart Werner
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112014010644A2 publication Critical patent/BR112014010644A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

resumo novos derivados de aril-quinolina a invenção proporciona novos compostos com a fórmula geral (i) em que r1, r2, r3, r4, r5, r6 e n são como aqui descritos, composições incluindo os compostos e métodos de uso dos compostos. 1/1
BR112014010644A 2011-11-04 2012-10-29 novos derivados de aril-quinolina BR112014010644A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11187967 2011-11-04
PCT/EP2012/071398 WO2013064465A1 (en) 2011-11-04 2012-10-29 New aryl-quinoline derivatives

Publications (1)

Publication Number Publication Date
BR112014010644A2 true BR112014010644A2 (pt) 2017-04-25

Family

ID=47115939

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014010644A BR112014010644A2 (pt) 2011-11-04 2012-10-29 novos derivados de aril-quinolina

Country Status (21)

Country Link
US (2) US9199938B2 (pt)
EP (1) EP2773619B1 (pt)
JP (1) JP6170060B2 (pt)
KR (1) KR20140088194A (pt)
CN (1) CN103906735B (pt)
AR (1) AR088625A1 (pt)
AU (1) AU2012331289B2 (pt)
BR (1) BR112014010644A2 (pt)
CA (1) CA2849945A1 (pt)
CL (1) CL2014001060A1 (pt)
CO (1) CO6930359A2 (pt)
CR (1) CR20140135A (pt)
EA (1) EA201490846A1 (pt)
ES (1) ES2609773T3 (pt)
IL (1) IL231950B (pt)
MX (1) MX343893B (pt)
MY (1) MY169267A (pt)
PE (1) PE20142282A1 (pt)
SG (1) SG11201401937YA (pt)
TW (1) TWI616437B (pt)
WO (1) WO2013064465A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20142282A1 (es) 2011-11-04 2015-01-08 Hoffmann La Roche Nuevos derivados de aril-quinolina
CA2873295A1 (en) * 2012-08-24 2014-02-27 F. Hoffmann-La Roche Ag New bicyclicpyridine derivatives
CN105294648B (zh) * 2015-11-30 2017-11-28 山东罗欣药业集团股份有限公司 一种西他沙星的制备方法
WO2017184547A1 (en) 2016-04-18 2017-10-26 New York University Quinoline compounds as modulators of rage activity and uses thereof
EP3246028A1 (en) * 2016-05-18 2017-11-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Quinoline compounds for increasing insuline release
JP7139323B2 (ja) 2016-11-01 2022-09-20 エフ．ホフマン－ラ ロシュ アーゲー Ｃｎｓ関連疾患を処置するための１，３－ジヒドロ－１，４－ベンゾジアゼピン－２－チオン
WO2018165120A1 (en) * 2017-03-06 2018-09-13 Gemphire Therapeutics Inc. Effect of carboxyalkylethers on obesity symptoms and lipodystropy
CN107311847B (zh) * 2017-07-12 2020-11-10 安徽省诚联医药科技有限公司 5-溴-2-氯-4′-乙氧基二苯甲烷的制备方法
CN109280028B (zh) * 2017-07-19 2022-03-25 上海医药工业研究院 喹啉类化合物及其在dpp-4酶抑制剂的应用
JP7403472B2 (ja) 2018-05-09 2023-12-22 バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 新規キノリン誘導体
US20200354374A1 (en) * 2019-05-06 2020-11-12 Inspira, LLC Chemical Entities, Pharmaceutical Formulations, and Methods for Treating Fibrosis
CN113277978B (zh) * 2021-06-02 2022-06-03 河南师范大学 一种2，4-双取代喹啉类化合物的制备方法
CN116693456A (zh) * 2022-02-28 2023-09-05 复旦大学 异喹啉酮类化合物及其制备方法和应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2569746B2 (ja) * 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
TW205037B (pt) * 1989-10-06 1993-05-01 Takeda Pharm Industry Co Ltd
US5371227A (en) 1991-10-28 1994-12-06 Synthelabo Quinoline derivatives, process for their preparation, and their therapeutic applications
NO179904C (no) * 1992-09-04 1997-01-08 Takeda Chemical Industries Ltd Kondenserte heterocykliske forbindelser og deres anvendelse
JP3724818B2 (ja) * 1992-09-04 2005-12-07 武田薬品工業株式会社 縮合複素環化合物、その製造法および剤
JPH0769890A (ja) * 1993-06-29 1995-03-14 Takeda Chem Ind Ltd キノリンまたはキナゾリン誘導体を含んでなる医薬組成物
JPH08225531A (ja) * 1994-03-08 1996-09-03 Takeda Chem Ind Ltd キノリンまたはキナゾリン誘導体を含んでなる医薬およびそれに用いる新規誘導体
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6900226B2 (en) 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists
WO2004018461A2 (en) * 2002-08-23 2004-03-04 Pharmacia & Upjohn Company Llc Antibacterial benzoic acid derivatives
KR101154431B1 (ko) * 2002-11-29 2012-06-15 주식회사 씨앤드씨신약연구소 치환된 1h-피리딘-2-온 유도체
WO2004063156A1 (en) * 2003-01-08 2004-07-29 Biovitrum Ab Novel indole derivates as fabp-4 inhibitors
CA2533626A1 (en) * 2003-07-22 2005-02-03 Janssen Pharmaceutica, N.V. Quinolinone derivatives as inhibitors of c-fms kinase
SE0302323D0 (sv) 2003-08-28 2003-08-28 Astrazeneca Ab Novel compounds
TW200825054A (en) 2006-10-18 2008-06-16 Wyeth Corp Quinoline compounds
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
AU2008303602A1 (en) 2007-09-27 2009-04-02 F. Hoffmann-La Roche Ag Quinoline derivatives as 5HT5A receptor antagonists
TW200940537A (en) 2008-02-26 2009-10-01 Astrazeneca Ab Heterocyclic urea derivatives and methods of use thereof
GB0818365D0 (en) 2008-10-07 2008-11-12 Argenta Discovery Ltd Quinoline compounds
EP2358716B1 (en) * 2008-11-12 2016-01-06 Merck Sharp & Dohme Corp. Inhibitors of fatty acid binding protein (fabp)
US20100125091A1 (en) * 2008-11-14 2010-05-20 Gilead Palo Alto, Inc. Substituted heterocyclic compounds as ion channel modulators
PE20142282A1 (es) 2011-11-04 2015-01-08 Hoffmann La Roche Nuevos derivados de aril-quinolina
MX2014005296A (es) 2011-11-04 2014-08-27 Afraxis Holdings Inc Inhibidores de pak para el tratamiento del sindrome del x fragil.
US9497965B2 (en) 2011-11-04 2016-11-22 Syngenta Participations Ag Pesticidal compounds

Also Published As

Publication number Publication date
CO6930359A2 (es) 2014-04-28
US20160060270A1 (en) 2016-03-03
CN103906735B (zh) 2016-12-07
CR20140135A (es) 2014-06-19
MX2014005373A (es) 2014-07-30
CA2849945A1 (en) 2013-05-10
TW201326130A (zh) 2013-07-01
NZ720278A (en) 2017-08-25
AU2012331289A1 (en) 2014-04-10
JP6170060B2 (ja) 2017-07-26
NZ622717A (en) 2016-06-24
EP2773619A1 (en) 2014-09-10
AU2012331289B2 (en) 2017-07-13
EA201490846A1 (ru) 2014-07-30
TWI616437B (zh) 2018-03-01
US9809599B2 (en) 2017-11-07
US9199938B2 (en) 2015-12-01
CL2014001060A1 (es) 2014-11-07
US20130116234A1 (en) 2013-05-09
EP2773619B1 (en) 2016-11-16
CN103906735A (zh) 2014-07-02
KR20140088194A (ko) 2014-07-09
IL231950B (en) 2018-02-28
MY169267A (en) 2019-03-20
MX343893B (es) 2016-11-28
SG11201401937YA (en) 2014-05-29
JP2014532681A (ja) 2014-12-08
PE20142282A1 (es) 2015-01-08
ES2609773T3 (es) 2017-04-24
WO2013064465A1 (en) 2013-05-10
AR088625A1 (es) 2014-06-25

Similar Documents

Publication Publication Date Title
BR112014010644A2 (pt) novos derivados de aril-quinolina
BR112015022804A2 (pt) novos derivados de octahidro-pirrol [3,4-c]-pirrol e seus análogos como inibidores de autotaxina
BR112014006660A2 (pt) novos derivados de dihidroquinolina-2-ona bicíclicos
TR201900038T4 (tr) GPR6'nın tetrahidropiridopirazin modülatörleri.
BR112013018732A2 (pt) novos derivados de amida de aril-benzocicloalquila
EA201590534A1 (ru) Новые бициклические производные
EA201492223A1 (ru) Новые диазаспироциклоалканы и азаспироциклоалканы
MY169043A (en) New dihydroquinoline-2-one derivatives
PH12014501179B1 (en) New bicyclic dihydroisoquinoline-1-one derivatives
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
BR112015023397A2 (pt) benzoxazois substituídos e métodos de uso dos mesmos
MX2014014531A (es) Derivados de aminoquinazolina y piridopirimidina.
BR112014003693A2 (pt) amino quinazolinas como inibidores de quinase
MA33937B1 (fr) Composes pyrazole comme antagonistes du recepteur crth2
BR112019006571A2 (pt) derivados de éter de isoxazolila como gaba a alfa5 pam
MX2015001099A (es) Nuevos derivados biciclicos de piridina.
MX2015013365A (es) Derivados de urea y su uso como inhibidores de proteina de union de acidos grasos (puag).
EA200801549A1 (ru) Новые производные фенантридина в качестве антагонистов брадикинина
BR112014030474A2 (pt) novos compostos bicíclicos de tiofenilamida
BR112013016431A2 (pt) novos derivados de amidas de biarila
BR112015028871A2 (pt) novos compostos de 3,4-dihidro-2h-isoquinolina-1-ona e 2,3-dihidro-isoindol-1-ona
BR112013024361A2 (pt) novos compostos de azaspirodecanona como inibidores de hsl
BR112013028368A2 (pt) novos compostos de hexahidrociclopentapirrolona, hexahidropirrolopirrolona, octahidropirrolopiridinona e octahidropiridinona
BR112015023280A2 (pt) derivados de dihidroquinolin-2-ona para utilização como inibidores da aldosterona sintase
MX2015013374A (es) Derivados de urea y su uso como inhibidores de proteina de uniuon a acidos grasos (puag).

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2538 DE 27-08-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]